Skip to main content

Table 2 Effect of hypertonic saline and furosemide on plasma concentrations of electrolytes in a randomized, cross-over study of 24 healthy subjects

From: Effect of 3% saline and furosemide on biomarkers of kidney injury and renal tubular function and GFR in healthy subjects – a randomized controlled trial

Period Baseline (90 min) After 60 min hypertonic saline infusion (150 min) 90 min post hypertonic saline infusion (240 min) P-value (difference in response)
p-Na (mmol/L)
 Placebo 140 ± 2 144 ± 2* 141 ± 2* 0.073
 Furosemide 139 ± 2 144 ± 2* 141 ± 2*
p-K (mmol/L)
 Placebo 3.8 ± 0.2 3.7 ± 0.2* 4.0 ± 0.2* 0.001
 Furosemide 3.7 ± 0.2 3.5 ± 0.2*, † 3.8 ± 0.2
p-Cl(mmol/L)
 Placebo 105 ± 2 111 ± 2* 107 ± 2* < 0.001
 Furosemide 104 ± 2 108 ± 2*, † 104 ± 2*, †
p-Osmolality (mmol/L)
 Placebo 282 ± 4 289 ± 3* 286 ± 4* 0.034
 Furosemide 282 ± 3 291 ± 3*, † 286 ± 3*
p-total carbondioxide (mmol/L)
 Placebo 27 ± 2 25 ± 2* 25 ± 2* < 0.001
 Furosemide 26 ± 2 26 ± 2 27 ± 2
  1. p-Na Plasma concentrations of sodium, p-K potassium, p-Cl chloride and total carbondioxide and plasma osmolality were measured every 30 min during examination. Data show are values before hypertonic saline infusion, after 60 min of saline infusion, and 90 min after cessation of saline infusion on the examination day. Data are shown as medians with 25 and 75 percentiles in brackets. P-value represents probability of difference in response to saline (response from baseline to saline infusion) between treatments. To test difference in response to saline between treatments a students t-test was used. Wilcoxon signed rank test was performed to test differences from baseline, * = p < 0.05, and from Placebo,  = p < 0.05